Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Short interest in Constellation Brands has risen to 5.5% of the free float, up 33% over the past month, even as the stock has recovered 8.7% over the past week to $122.64. The divergence between a recovering price and a growing short position is the defining tension around STZ right now.
Short interest stood at 9.57 million shares as of October 9. A month ago it was closer to 7.2 million. The build has been steady, not a single-day spike. The lending market offers no constraint: availability stands at 3,968%, meaning there are roughly 40 shares available to borrow for every one already lent out. Cost to borrow is negligible at 0.21%. None of the usual friction that accompanies a crowded short is present here.
The options market is similarly unmoved. The put/call ratio sits at 0.83, essentially in line with its 20-day average of 0.83. There is no sign of hedging pressure or directional urgency from derivatives traders.
Since the October 7 earnings print, every analyst revision has cut the price target. HSBC's Sorabh Daga made the most dramatic move, downgrading to Hold and cutting the target 30% to $135 from $192. JP Morgan's Drew Levine has now raised the target slightly to $136 from $133, maintaining Neutral. That modest upward tweak is the exception. Piper Sandler cut to $125 from $161. Deutsche Bank sits at $127. Morgan Stanley at $145. Needham at $150.
The consensus mean target is $151.74. The stock at $122.64 implies roughly 24% upside on paper, but that gap has been persistently wide for weeks while the targets themselves keep falling. Freedom Broker did upgrade to Buy this week, cutting the target to $158 from $173. It is one constructive voice among many cautious ones.
One signal cuts across the bearish flow. ORTEX Alt Data shows retail attention spiking 3.2 standard deviations above its own 90-day average, as measured by Wikipedia pageviews and ORTEX stock page traffic as of October 8. That is a large move. It reflects attention, not positioning, and the dataset carries no measured lead to the company's reported figures. But a 3.2 standard deviation reading in retail interest, arriving alongside a 33% one-month short build and a wave of analyst cuts, suggests the stock is drawing a crowd from multiple directions.
Separately, ORTEX forecasts a 52% chance of STZ joining the CRSP US Small index at the December 2026 Quarterly Review. The stock would need to close above $123.76 to meet the entry line. It closed at $122.64 on October 9. That $1.12 gap, if crossed, would require index trackers to buy an estimated $307 million of stock on the trade date of December 22.
See the live data behind this article on ORTEX.
Open STZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
